scholarly journals A nonsense mutation in the DNA repair factor Hebo causes mild bone marrow failure and microcephaly

2016 ◽  
Vol 213 (6) ◽  
pp. 1011-1028 ◽  
Author(s):  
Shu Zhang ◽  
Corinne Pondarre ◽  
Gaelle Pennarun ◽  
Helene Labussiere-Wallet ◽  
Gabriella Vera ◽  
...  

Inherited bone marrow failure syndromes are human conditions in which one or several cell lineages of the hemopoietic system are affected. They are present at birth or may develop progressively. They are sometimes accompanied by other developmental anomalies. Three main molecular causes have been recognized to result in bone marrow failure syndromes: (1) defects in the Fanconi anemia (FA)/BRCA DNA repair pathway, (2) defects in telomere maintenance, and (3) abnormal ribosome biogenesis. We analyzed a patient with mild bone marrow failure and microcephaly who did not present with the typical FA phenotype. Cells from this patient showed increased sensitivity to ionizing radiations and phleomycin, attesting to a probable DNA double strand break (dsb) repair defect. Linkage analysis and whole exome sequencing revealed a homozygous nonsense mutation in the ERCC6L2 gene. We identified a new ERCC6L2 alternative transcript encoding the DNA repair factor Hebo, which is critical for complementation of the patient’s DNAdsb repair defect. Sequence analysis revealed three structured regions within Hebo: a TUDOR domain, an adenosine triphosphatase domain, and a new domain, HEBO, specifically present in Hebo direct orthologues. Hebo is ubiquitously expressed, localized in the nucleus, and rapidly recruited to DNAdsb’s in an NBS1-dependent manner.

2018 ◽  
Vol 115 (30) ◽  
pp. 7777-7782 ◽  
Author(s):  
Hemanth Tummala ◽  
Arran D. Dokal ◽  
Amanda Walne ◽  
Alicia Ellison ◽  
Shirleny Cardoso ◽  
...  

Biallelic variants in the ERCC excision repair 6 like 2 gene (ERCC6L2) are known to cause bone marrow failure (BMF) due to defects in DNA repair and mitochondrial function. Here, we report on eight cases of BMF from five families harboring biallelic variants in ERCC6L2, two of whom present with myelodysplasia. We confirm that ERCC6L2 patients’ lymphoblastoid cell lines (LCLs) are hypersensitive to DNA-damaging agents that specifically activate the transcription coupled nucleotide excision repair (TCNER) pathway. Interestingly, patients’ LCLs are also hypersensitive to transcription inhibitors that interfere with RNA polymerase II (RNA Pol II) and display an abnormal delay in transcription recovery. Using affinity-based mass spectrometry we found that ERCC6L2 interacts with DNA-dependent protein kinase (DNA-PK), a regulatory component of the RNA Pol II transcription complex. Chromatin immunoprecipitation PCR studies revealed ERCC6L2 occupancy on gene bodies along with RNA Pol II and DNA-PK. Patients’ LCLs fail to terminate transcript elongation accurately upon DNA damage and display a significant increase in nuclear DNA–RNA hybrids (R loops). Collectively, we conclude that ERCC6L2 is involved in regulating RNA Pol II-mediated transcription via its interaction with DNA-PK to resolve R loops and minimize transcription-associated genome instability. The inherited BMF syndrome caused by biallelic variants in ERCC6L2 can be considered as a primary transcription deficiency rather than a DNA repair defect.


Blood ◽  
2020 ◽  
Author(s):  
Frederick D Tsai ◽  
R. Coleman Lindsley

Inherited bone marrow failure syndromes (IBMFS) are characterized by ineffective hematopoiesis and increased risk of developing myeloid malignancy. The pathophysiologies of different IBMFS are variable, and can relate to defects in diverse biological processes, including DNA damage repair (Fanconi anemia), telomere maintenance (dyskeratosis congenita), and ribosome biogenesis (Diamond-Blackfan anemia, Shwachman-Diamond syndrome). Somatic mutations leading to clonal hematopoiesis have been described in IBMFS, but the distinct mechanisms by which mutations drive clonal advantage in each disease and their associations with leukemia risk are not well understood. Clinical observations and laboratory models of IBMFS suggest that the germline deficiencies establish a qualitatively impaired functional state at baseline. In this context, somatic alterations can promote clonal hematopoiesis by improving the competitive fitness of specific hematopoietic stem cell clones. Some somatic alterations relieve baseline fitness constraints by normalizing the underlying germline deficit through direct reversion or indirect compensation, while others do so by subverting senescence or tumor suppressor pathways. Clones with normalizing somatic mutations may have limited transformation potential due to retention of functionally intact fitness-sensing and tumor suppressor pathways, while those with mutations that impair cellular elimination may have increased risk of malignant transformation due to subversion of tumor suppressor pathways. Since clonal hematopoiesis is not deterministic of malignant transformation, rational surveillance strategies will thus depend on the ability to prospectively identify specific clones with increased leukemic potential. We describe a framework by which an understanding of the processes that promote clonal hematopoiesis in IBMFS may inform clinical surveillance strategies.


Blood ◽  
2008 ◽  
Vol 112 (9) ◽  
pp. 3594-3600 ◽  
Author(s):  
Amanda J. Walne ◽  
Tom Vulliamy ◽  
Richard Beswick ◽  
Michael Kirwan ◽  
Inderjeet Dokal

Abstract Dyskeratosis congenita (DC) is a multisystem bone marrow failure syndrome characterized by a triad of mucocutaneous abnormalities and a predisposition to cancer. The genetic basis of DC remains unknown in more than 60% of patients. Mutations have been identified in components of the telomerase complex (dyskerin, TERC, TERT, NOP10, and NHP2), and recently in one component of the shelterin complex TIN2 (gene TINF2). To establish the role of TINF2 mutations, we screened DNA from 175 uncharacterised patients with DC as well as 244 patients with other bone marrow failure disorders. Heterozygous coding mutations were found in 33 of 175 previously uncharacterized DC index patients and 3 of 244 other patients. A total of 21 of the mutations affected amino acid 282, changing arginine to histidine (n = 14) or cysteine (n = 7). A total of 32 of 33 patients with DC with TINF2 mutations have severe disease, with most developing aplastic anaemia by the age of 10 years. Telomere lengths in patients with TINF2 mutations were the shortest compared with other DC subtypes, but TERC levels were normal. In this large series, TINF2 mutations account for approximately 11% of all DC, but they do not play a significant role in patients with related disorders. This study emphasises the role of defective telomere maintenance on human disease.


Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 2410-2410
Author(s):  
Aparna Raval ◽  
Brenda Kusler ◽  
Steven Artandi ◽  
Beverly S. Mitchell

Abstract Abstract 2410 Telomere shortening and anemia are common in bone marrow failure syndromes (BMF) such as dyskeratosis congenita (DKC), acquired aplastic anemia and myelodysplastic syndromes (MDS). Components of the telomerase complex including TERT, TERC and Dyskerin are mutated in multiple BMF syndromes, strongly suggesting a link between aberrant telomere maintenance and BMF. However, the specific defects in hematopoiesis that lead to BMF have not been completely defined. To better understand the effects of telomere shortening on hematopoiesis, we crossed Tert−/− mice for five successive generations to derive 5th generation Tert−/− (G5 Tert−/−) mice with short telomeres. The G5 Tert−/− mice were smaller in size and their peripheral blood cell counts had significantly reduced numbers of red blood cells and hemoglobin content (p-value < 0.01). There was also a significant reduction in immature erythroid (CD71+; p-value < 0.03) and mature erythroid (CD71-Ter119+; p-value < 0.05) cells in the bone marrows of these mice as compared to the G0 Tert+/− controls, while myeloid (Mac-1, Gr1+) cell numbers were not decreased. Annexin V and PI staining showed increased apoptosis in immature erythroid cells from G5 Tert−/− mice. In order to determine if the reduction in erythrocytes was due to defective hematopoiesis, we studied hematopoietic stem cell (HSC), committed erythroid progenitor (MEP) and myeloid progenitor (GMP) cell numbers in these mice. We observed a marked decrease in MEP (Lin-cKit+Sca1-CD34-CD16/CD32lo; p-value < 0.02) and HSC (Lin-cKit+Sca1+CD34-CD150+; p-value < 0.03) populations in G5 Tert−/− mice marrow, while GMP (Lin-cKit+Sca1-CD34+CD16/CD34hi; p-value < 0.6) cells were not affected. In contrast, there was an increase in the number of immature erythroid cells (CD71+), hematopoietic progenitor cells (Lin-cKit+Sca1+) and HSC in the spleens of G5 Tert−/− mice, strongly suggesting extramedullary hematopoiesis. These data demonstrate that there is a defect in the regulation of hematopoiesis, starting at the level of HSC, in the bone marrow of G5 Tert−/− mice. MEPs from G5 Tert−/− mice showed increased DNA damage, as demonstrated by phospho-H2Ax staining by flow cytometry, although enhanced apoptosis was not present. In contrast, GMPs did not show any difference in phospho-H2Ax staining, suggesting that MEPs may be selectively sensitive to telomere shortening or that telomeres shorten more rapidly in these cells. Total bone marrow cells from G0 Tert+/− and G5 Tert−/− mice were plated in Methocult supporting erythroid colony formation; we observed that the G5 Tert−/− cells had significantly reduced numbers of CFU-E and BFU-E colonies (p-value < 0.01) compared to cells from the G0 mice, suggesting that the ability of erythroid progenitor cells to differentiate is compromised by dysfunctional telomeres. These data show for the first time a direct and distinctive link between the loss of telomerase function and erythropoiesis. These results, in conjunction with single-cell “mass cytometry” experiments to explore the molecular pathways that are selectively deregulated in the HSC and erythroid precursors of G5 Tert−/− mice, will elucidate the mechanisms underlying the cell-specific effects of telomere shortening on erythropoiesis and help to elucidate the relationship between shortened telomeres and the anemia of bone marrow failure syndromes. Disclosures: No relevant conflicts of interest to declare.


2021 ◽  
pp. 43-61
Author(s):  
Amy E. Geddis ◽  
Meera Srikanthan ◽  
Katie Bergstrom

Sign in / Sign up

Export Citation Format

Share Document